Background and Objectives
Endometrial hyperplasia (EH) is an abnormal overgrowth of endometrium that may lead to endometrial cancer, especially when accompanied by atypia [1] .
Although the effect appears only in 5% of asymptomatic patients, its prevalence in patients with PCOS and oligomenorrhea is about 20% [2] . Body mass index (BMI) and nulliparity are two main risk factors for EH. Other risk factors include chronic anovulation, early menarche, late onset of menopause and diabetes [3] , which are related to increased circulating estrogen [4] . The treatment of EH is challenging and previous studies report conflicting results [5] . Age, fertility, and severity of EH in histology are the most important factors determining the treatment option [5] . Most studies have addressed hysterectomy in patients with atypical EH [5] , particularly those with PCOS, and have led to conflicting results [5] [6] [7] [8] [9] [10] [11] .
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cularization as a biological bypass of the atherosclerotic vessels may improve the symptoms in patients with the severe ischemic cardiac disease who cannot benefit from the conventional percutaneous coronary intervention or CABG. 2 Thus far, numerous inducers of angiogenesis have been identified, including the members of the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), 4 transforming growth factor-α and -β (TGF-α and -β), 5 chemokines, interleukins, and the members of the fibroblast growth factor (FGF) family. 6 Studies reported that basic FGF, also known as FGF-2 have a strong affinity for the extracellular matrix and basal lamina and also paracrine, autocrine and intracellular modes of action. 7 It is reported that FGF-2 may improve the survival rate in patients with the ischemic heart disease if it is administered before, during or after the injury. 8 Furthermore, exogenous administration of FGF in different animal models of chronic myocardial ischemia or acute infarction showed increased myocardial perfusion and preserved left ventricular function. 9, 10 In this double-blind, placebo-controlled study we evaluated the effectiveness and safety of angiogenic protein therapy by implantation of sustained-release alginate-heparin-sepharose microspheres capsules of FGF-2 in the ischemic myocardium of patients who underwent CABG.
Methods

Patient Selection
Eighteen patients who were eligible for CABG were included in this study, which was performed at the Tehran ose microcapsules each contains 100 mcg FGF-2 were implanted in the subepicardial layer of the diffusely defective LAD territory via 2-3 mm stab incisions. 3 After the implantation, the epicardial incisions were sutured with 5-0 polypropylene. Afterward, proximal anastomoses were performed, the aorta was unclamped and the patients were separated from CPB and the chest was closed normally. 
Results
Patients' Characteristics
Eighteen patients who met the inclusion and exclusion criteria were divided into two groups. Ten patients were allocated to bFGF group and 8 patients were allocated to control group. During the process of this study, 2 patients of the bFGF group were excluded, because they refused to participate in the follow up evaluations. Also, 2 patients (one from each group) were withdrawn from the study since they could not be located for follow up. Finally, 7
patients in each group were investigated till the end of this study. Patients were randomly assigned into two groups and there were no significant demographic differences between them. Preoperative characteristics of patients are summarized in Table 1 According to the 2 dimensional echocardiography, there 
Perfusion Scans
According to myocardial perfusion scan and uptake of radioactive material we had three types of segments as listed here; (1) normal uptake segment, (2) mild to moderate uptake segment, and (3) segment with severely decreased to absent uptake. Nine segments were defined for the LAD related area. There were improvements in perfusion scores within the FGF-2 group while this finding was not observed in the control group. This improvement included increases in the number of segments with normal uptake and reduction in the number of segments with mild to moderate or severely decreased or absent uptake (P < 0.001, P < 0.001 and P = 0.003 respectively). We compared changes in perfusion scan between 2 groups which is summarized in Table 2 . There was a significant difference between the FGF-2 treated and control group in the changes of the number of severely decreased to absent and normal uptake segments (P = 0.03, P = 0.01). This finding was not observed before the intervention. Comparison of changes in perfusion scores between the 2 groups is shown in Figure 1 .
The mean summed stress score was not significantly different between FGF-2 and control groups before the intervention (17.571 ± 3.20 vs. 17.85 ± 6.01, P = 0.138).
However, patients in the FGF-2 group had significantly lower score, 6 months after the surgery (5.428 ± 7.299 vs. 14.857 ± 3.976, P = 0.011). This score was significantly reduced in the FGF-2 group after 6 months of follow up (5.428 ± 7.299 vs. 17.571 ± 3.20, P = 0.001) in contrast to the control group who did not show a significantly lower score 6 months after the intervention (14.857 ± 3.976 vs.
17.857 ± 6.011, P = 0.156).
Postoperation Side Effects
No 
Discussion
Up to 37% of patients with ischemic heart disease, suffer from a diffuse and severe CAD that neither can undergo percutaneous coronary intervention nor surgical bypass to restore the normal blood flow. 13 Therapeutic angiogenesis can be considered as an option in the management of these patients. Protein therapy poses some advantages since it can be delivered directly to the target area, its quantity can be controlled more accurately, can immediately affect the target tissue and probably causes minimum inflammatory and immune adverse effect compared to the other methods. 14, 15 More importantly, it does not require complicated methods of gene therapy or the exposure to foreign genetic materials with unknown longterm outcomes. 16 The aim of this study was to evaluate the effectiveness and the safety of administering FGF-2 for therapeutic angiogenesis in ischemic myocardium of patients who undergo CABG. Administration of FGF-2 at the onset of ischemia is reported to reduce injury and attenuate heart enzymes. 17, 18 It can be a promising choice of pretreatment in CABG to reduce the ischemic injury of cross-clamp time. Nakamae et al reported that FGF-2 enhanced vascular density in necrotic iliac bone in rabbits. in infarcted canine heart model; also FGF increased the reported a better physical well-being 3 and 6 months after the intervention in FGF-2 receiving group. However, this improvement was not significantly higher in the FGF-2 group compared to the control group. 24 Most of the previous studies reported FGF-2 increased ventricular ejection fraction in patients receiving FGF compared to control group. 26 In line with these findings, in the present study, left side ventricular ejection fraction improved significantly in FGF group 6 months after the surgery while this finding was not observed in the control group. Myocardial perfusion scan was performed 6 months after the intervention in all patients. In the FGF group, segments with impaired uptake significantly decreased while this finding was not significant in the control group.
In a phase I clinical trial by Sellke et al the result of perfusion scan 3 months after surgery of 7 patients receiving FGF showed enhanced perfusion in 3, minimal changes in 3 and the appearance of new small defects in 1 patient. 12 However, Simons et al reported no significant difference in myocardial perfusion of patients in FGF-2 group and the control group after 6 months of follow-up. 23 with viable myocardium that cannot be adequately revascularized. Also, reduction in the target ischemic area in the 100-mg bFGF group was shown via magnetic resonance assessment. 3 Another concern regarding the use of FGF-2 is its safety due to its probable side effects, including acute severe hypotension and renal insufficiency. 16, 36 According to the previous studies, single local administration of FGF-2 seems to be well-tolerated and safe. 12, 16, 23 In our study, no patient showed any serious side effect. However, since 2 patients in the FGF-2 group did not participate in the follow-up evaluations after the intervention, and 2 patients, one from the FGF-2 group and another from control group could not be located till the end of the follow-up period, accurate evaluation of side effects and mortality could not be performed. 
Study Limitations
Conclusions
The present study was aimed to evaluate the effectiveness and safety of therapeutic angiogenesis using basic 
